BMI downgrades growth forecast for Pakistan pharma market in 2nd-qtr 2010

14 April 2010

Pakistan's macroeconomic indicators have deteriorated significantly since first-quater 2010. The rupee has depreciated against the US dollar, gross domestic product (GDP) projections have been downgraded, inflation has increased and fiscal expenditure has contracted, notes Business Monitor International's Pakistan Pharmaceuticals and Healthcare Report. Therefore, Pakistan's $1.61 billion pharmaceutical market is now expected to post a five-year compound annual growth rate of 8.95%, down from 9.39% forecast in the previous quarter.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Generics